Abstract
Over the past two decades, considerable advances have been made in our understanding of the renin–angiotensin–aldosterone system (RAAS) and its roles in various disease states. In this review, we will discuss the current state of knowledge of the many components of the RAAS, including new data on prorenin and its receptors, and important angiotensin fragments. The roles of these components of the RAAS in the pathogenesis of primary hypertension and the progression of chronic kidney disease (CKD) will also be highlighted. Given the new understanding of the many components and roles of the RAAS, it may be possible to develop improved therapies for hypertension and CKD.
Similar content being viewed by others
References
Phillips MI, Schmidt-Ott KM (1999) The discovery of renin 100 years ago. News Physiol Sci 14:271–274
Basso N, Terragno NA (2001) History about the discovery of the renin-angiotensin system. Hypertension 38:1246–1249
Taquini AC Jr, Taquini AC (1961) The renin-angiotensin system in hypertension. Am Heart J 62:558–564
Gavras H, Brunner HR, Laragh JH, Sealey JE, Gavras I, Vukovich RA (1974) An angiotensin converting-enzyme inhibitor to identify and treat vasoconstrictor and volume factors in hypertensive patients. N Engl J Med 291:817–821
Streeten DHP, Anderson GH, Freiberg JM, Dalakos TG (1975) Use of an angiotensin II antagonist (Saralasin) in the recognition of angiotensinogenic hypertension. N Engl J Med 292:657–662
Griendling KK, Murphy TJ, Alexander RW (1993) Molecular biology of the renin-angiotensin system. Circulation 87:1816–1828
Esther CR, Marino EM, Howard TE, Machaud A, Corvol P, Capecchi MR, Bernstein KE (1997) The critical role of tissue angiotensin-converting enzyme as revealed by gene targeting in mice. J Clin Invest 99:2375–2385
Mukoyama M, Nakajima M, Horiuchi M, Sasamura H, Pratt RE, Dzau VJ (1993) Expression cloning of type 2 angiotensin II receptor reveals a unique class of seven-transmembrane receptors. J Biol Chem 268:24539–24542
Iwai N, Inagami T (1992) Identification of two subtypes in the rat type I angiotensin II receptor. FEBS Lett 298:257–260
Yamaguchi I, Flynn JT (2009) Pathophysiology of hypertension. In: Avner E, Harmon W, Niaudet P, Yoshikawa N (eds) Pediatric nephrology, 6th edn. Lippincott Williams and Wilkins, Philadelphia, PA, pp 1485–1518
Santos RA, Ferreira AJ, Simões e Silva AC (2008) Angiotensins. In: Bader M (ed) Cardiovascular hormone systems: from molecular mechanisms to novel therapeutics, 1st edn. Wiley-VCH, Weinheim, pp 67–100
Lavoie JL, Sigmund CD (2003) Minireview: overview of the renin-angiotensin system—an endocrine and paracrine system. Endocrinology 144:2179–2183
Ganten D, Marquez-Julio A, Granger P, Hayduk K, Karsunky KP, Boucher R, Genest J (1971) Renin in dog brain. Am J Physiol 221:1733–1737
Miyazaki M, Takai S (2006) Tissue angiotensin II generating system by angiotensin-converting enzyme and chymase. J Pharmacol Sci 100:391–397
Spät A, Hunyady L (2004) Control of aldosterone secretion: a model for convergence in cellular signaling pathways. Physiol Rev 84:489–539
Sernia C (2001) A critical appraisal of the intrinsic pancreatic angiotensin-generating system. J Pancreas 2:50–55
Nielsen AH, Schauser KH, Poulsen K (2000) Current topic: the uteroplacental renin-angiotensin system. Placenta 21:468–477
Santos RA, Ferreira AJ, Simões e Silva AC (2008) Recent advances in the mammalian angiotensin-converting enzyme 2- angiotensin-(1–7)-Mas axis. Exp Physiol w93:519–527
Albiston AL, McDowall SG, Matsacos D, Sim P, Clune E, Mustafa T, Lee J, Mendelsohn FA, Simpson RJ, Connolly LM, Chai SY (2004) Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 276:48623–48626
Santos RAS, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T (2003) Angiotensin-(1–7) is an endogenous ligand for the G protein-coupled receptor Mas. Proc Natl Acad Sci USA 100:8258–8263
Nguyen G, Delarue F, Burckle C, Bouzhir L, Giller T, Sraer JD (2002) Pivotal role of the renin/prorenin receptor in angiotensin II production and cellular responses to renin. J Clin Invest 109:1417–1427
Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S (2000) A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1–9. Circ Res 87:E1–E9
Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ (2000) A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 275:33238–33243
Kohlstedt K, Brandes RP, Muller-Esterl W, Busse R, Fleming I (2004) Angiotensin-converting enzyme is involved in outside-in signaling in endothelial cells. Circ Res 94:60–67
Abdalla S, Lother H, Quitterer U (2000) AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. Nature 407:94–98
Staessen JA, Li Y, Richart T (2006) Oral renin inhibitors. Lancet 368:1449–1456
Nguyen G, Muller DN (2010) The biology of the (pro)renin receptor. J Am Soc Nephrol 21:18–23
Nguyen G (2011) Renin, (pro)renin and receptor: an update. Clin Sci (Lond) 120:169–178
Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P (2002) Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem 277:14838–14843
Oudit GY, Herzenberg AM, Kassiri Z, Wong D, Reich H, Khokha R, Crackower MA, Backx PH, Penninger JM, Scholey JW (2006) Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. Am J Pathol 168:1808–1820
Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D (2006) ACE and ACE2 activity in diabetic mice. Diabetes 55:2132–2139
Ye M, Wysocki J, William J, Soler MJ, Cokic I, Batlle D (2006) Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: implications for albuminuria in diabetes. J Am Soc Nephrol 17:3067–3075
Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, Herzenberg AM, Scholey JW (2007) Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171:438–451
Soler MJ, Wysocki J, Ye M, Lloveras J, Kanwar Y, Batlle D (2007) ACE2 inhibition worsens glomerular injury in association with increased ACE expression in streptozotocin-induced diabetic mice. Kidney Int 72:614–623
Dilauro M, Zimpelmann J, Robertson SJ, Genest D, Burns KD (2010) Effect of ACE2 and angiotensin-(1–7) in a mouse model of early chronic kidney disease. Am J Physiol Renal Physiol 298:F1523–F1532
Silveira KD, Pompermayer Bosco KS, Diniz LR, Carmona AK, Cassali GD, Bruna-Romero O, de Sousa LP, Teixeira MM, Santos RA, Simões e Silva AC, Ribeiro Vieira MA (2010) ACE2-angiotensin-(1–7)-Mas axis in renal ischaemia/reperfusion injury in rats. Clin Sci (Lond) 119:385–394
Ferrario CM (2011) ACE2: more of Ang-(1–7) or less Ang II? Curr Opin Nephrol Hypertens 20:1–6
Santos RAS, Brosnihan KB, Chappell MC, Pesquero J, Chernicky CL, Greene LJ, Ferrario CM (1998) Converting enzyme activity and angiotensin metabolism in the dog brainstem. Hypertension 11:I153–I157
Schiavone MT, Santos RAS, Brosnihan KB, Khosla MC, Ferrario CM (1988) Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1–7) heptapeptide. Proc Natl Acad Sci USA 85:4095–4098
Campagnole-Santos MJ, Diz DI, Santos RAS, Khosla MC, Brosnihan KB, Ferrario CM (1989) Cardiovascular effects of angiotensin-(1–7) injected into the dorsal medulla of rats. Am J Physiol 257:H324–H329
Sampaio WO, Nascimento AA, Santos RAS (2003) Systemic and regional hemodynamics effects of angiotensin-(1–7) in rats. Am J Physiol 284:H1985–H1994
Mostard GJM, Houben AJHM, Kroon AA, van Engelshoven JMA, de Leeuw PW (2007) Angiotensin 1–7 induces renal vasodilation in hypertensive patients independent of an activated renin-angiotensin system [abstract]. Hypertension 50:804
Botelho-Santos GA, Sampaio WO, Reudelhuber TL, Bader M, Campagnole-Santos MJ, Santos RAS (2007) Expression of an angiotensin-(1–7)-producing fusion protein in rats induced marked changes in regional vascular resistance. Am J Physiol Heart Circ Physiol 292:H2485–H2490
Ren Y, Garvin JL, Carretero OA (2002) Vasodilator action of angiotensin-(1–7) on isolated rabbit afferent arterioles. Hypertension 39:799–802
Andreatta-van Leyen S, Romero MF, Khosla MC, Douglas JG (1993) Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1–7). Kidney Int 44:932–936
Handa RK (1999) Angiotensin-(1–7) can interact with the rat proximal tubule AT(4) receptor system. Am J Physiol 277:F75–F83
DelliPizzi AM, Hilchey SD, Bell-Quilley CP (1994) Natriuretic action of angiotensin(1–7). Br J Pharmacol 111:1–3
Lara LS, Vives D, Correa JS, Cardozo FP, Marques-Fernades MF, Lopes AG, Caruso-Neves C (2010) PKA-mediated effect of MAS receptor in counteracting angiotensin II-stimulated renal Na + −ATPase. Arch Biochem Biophys 496:117–22
Santos RAS, Simões e Silva AC, Magaldi AJ, Khosla MC, Cesar KR, Passaglio KT, Baracho NC (1996) Evidence for a physiologic role of angiotensin-(1–7) in the control of hydroelectrolyte balance. Hypertension 27:875–884
Simões e Silva AC, Baracho NCV, Passaglio KT, Santos RAS (1997) Renal actions of Angiotensin-(1–7). Braz J Med Biol Res 30:503–513
Magaldi AJ, Cesar KR, Araujo M, Simões e Silva AC, Santos RAS (2003) Angiotensin-(1–7) stimulates water transport in rat inner medullary collecting duct: evidence for involvement of vasopressin V2 receptors. Pflugers Arch 447:223–230
Simões e Silva AC, Bello APC, Baracho NCV, Khosla MC, Santos RAS (1998) Diuresis and natriuresis produced by long term administration of a selective angiotensin-(1–7) antagonist in normotensive and hypertensive rats. Regul Pept 74:177–184
Santos RA, Haibara AS, Campagnole-Santos MJ, Simões e Silva AC, Paula RD, Pinheiro SVB, Leite MF, Lemos VS, Silva DR, Guerra MT, Khosla MC (2003) Characterization of a new selective antagonist for Angiotensin-(1–7), D-Pro7–Angiotensin-(1–7). Hypertension 41:737–743
Pinheiro SV, Simões e Silva AC, Sampaio WO, Paula RD, Mendes EP, Bontempo ED, Pesquero JB, Walther T, Alenina N, Bader M, Bleich M, Santos RAS (2004) Nonpeptide AVE 0991 is an angiotensin-(1–7) receptor Mas agonist in the mouse kidney. Hypertension 44:490–496
Pinheiro SV, Ferreira AJ, Kitten GT, Silveira KD, Silva DA, Santos SH, Gava E, Castro CH, Magalhaes JA, Mota RK, Botelho-Santos GA, Bader M, Alenina N, Santos RA, Simões e Silva AC (2009) Genetic deletion of the angiotensin-(1–7) receptor Mas leads to glomerular hyperfiltration and microalbuminuria. Kidney Int 75:1184–1193
Esteban V, Heringer-Walther S, Sterner-Kock A, de Bruin R, van den Engel S, Wang Y, Mezzano S, Egido J, Schultheiss HP, Ruiz-Ortega M, Walther T (2009) Angiotensin-(1–7) and the G protein-coupled receptor Mas are key players in renal inflammation. PLoS One 4:e5406
Zhang J, Noble NA, Border WA, Huang Y (2010) Infusion of angiotensin-(1–7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. Am J Physiol Renal Physiol 298:F579–F588
Velkoska E, Dean RG, Griggs K, Burchil LJ, Burrell LM (2011) Angiotensin 1–7 infusion is associated with increased blood pressure and adverse cardiac remodeling in rats with subtotal nephrectomy. Clin Sci (Lond) 120:335–345
Su Z, Zimpelmann J, Burns KD (2006) Angiotensin-(1–7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69:2212–2218
Zimpelmann J, Burns KD (2009) Angiotensin-(1–7) activates growth stimulatory pathways in human mesangial cells. Am J Physiol Renal Physiol 296:F337–346
van der Wouden EA, Ochodnick P, van Dokkum RP, Roks AJ, Deelman LE, de Zeeuw D, Henning RH (2006) The role of angiotensin(1–7) in renal vasculature of the rat. J Hypertens 24:1971–1978
Ocaranza MP, Godoy I, Jalil JE, Varas M, Collantes P, Pinto M, Roman M, Ramirez C, Copaja M, Diaz-Araya G, Castro P, Lavandero S (2006) Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat. Hypertension 48:572–578
Rice GI, Thomas DA, Grant PJ, Turner AJ, Hooper NM (2004) Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J 383:45–51
Kramkowski K, Mogielnicki A, Buczko W (2006) The physiologic significance of the alternative pathways of angiotensin II production. J Physiol Pharmacol 57:529–539
Li N, Zimpelmann J, Cheng K, Wilkins JA, Burns KD (2005) The role of angiotensin converting enzyme 2 in the generation of angiotensin 1–7 by rat proximal tubules. Am J Physiol Renal Physiol 288:F353–F362
Velez JC, Bland AM, Arthur JM, Raymond JR, Janech MG (2007) Characterization of renin-angiotensin system enzyme activities in cultured mouse podocytes. Am J Physiol Renal Physiol 293:F398–F407
Jackman HL, Massad MG, Sekosan M, Tan F, Brovkovych V, Marcic BM, Erdos EG (2002) Angiotensin 1–9 and 1–7 release in human heart: role of cathepsin A. Hypertension 39:976–981
Mogielnicki A, Kramkowski K, Chabielska E, Buczko W (2003) Angiotensin 1–9 influences hemodynamics and hemostatics parameters in rats. Pol J Pharmacol 55:503–504
Kramkowski K, Mogielnicki A, Leszczynska A, Buczko W (2010) Angiotensin-(1–9), the product of angiotensin I conversion in platelets, enhances arterial thrombosis in rats. J Physiol Pharmacol 61:317–324
Karwowska-Polecka W, Kulakowska A, Wisniewski K, Braszko JJ (1997) Losartan influences behavioural effects of angiotensin II(3–7) in rats. Pharmacol Res 36:275–283
Ferreira PM, Santos RAS, Campagnole-Santos MJ (2007) Angiotensin-(3–7) pressor effect at the rostral ventrolateral medulla. Regul Pept 141:168–174
Jankowski V, Vanholder R, van der Giet M, Tolle M, Karadogan S, Gobom J, Furkert J, Oksche A, Krause E, Tran TN, Tepel M, Schuchardt M, Schluter H, Wiedon A, Beyermann M, Bader M, Todiras M, Zidek W, Jankowski J (2007) Mass-spectrometric identification of a novel angiotensin peptide in human plasma. Arterioscler Thromb Vasc Biol 27:297–302
Nagata S, Kato J, Sasaki K, Minamino N, Eto T, Kitamura K (2006) Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system. Biochem Biophys Res Comm 350:1026–1031
Isa K, García-Espinosa MA, Arnold AC, Pirro NT, Tommasi EN, Ganten D, Chappell MC, Ferrario CM, Diz DI (2009) Chronic immunoneutralization of brain angiotensin-(1–12) lowers blood pressure in transgenic (mRen2)27 hypertensive rats. Am J Physiol Regul Integr Comp Physiol 297:R111–R115
Ferrario CM, Varagic J, Habibi J, Nagata S, Kato J, Chappell MC, Trask AJ, Kitamura K, Whaley-Connell A, Sowers JR (2009) Differential regulation of angiotensin-(1–12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol 296:H1184–H1192
Ahmad S, Varagic J, Westwood BM, Chappell MC, Ferrario CM (2011) Uptake and metabolism of the novel Peptide Angiotensin-(1–12) by neonatal cardiac myocytes. PLoS One 6:e15759
Kohara K, Brosnihan KB, Ferrario CM (1993) Angiotensin-(1–7) in the spontaneously hypertensive rat. Peptides 14:883–891
Campbell DJ, Duncan AM, Kladis A, Harrap SB (1995) Angiotensin peptides in spontaneously hypertensive and normotensive donryu rats. Hypertension 25:928–934
Ferrario CM, Martell N, Yunis C, Flack JM, Chappell MC, Brosnihan KB, Dean RH, Fernandez A, Novikov SV, Pinillas C, Luque M (1998) Characterization of angiotensin-(1–7) in the urine of normal and essential hypertensive subjects. Am J Hypertens 11:137–146
Simões e Silva AC, Diniz JSS, Regueira Filho A, Santos RAS (2004) The Renin Angiotensin System in childhood hypertension: selective increase of Angiotensin-(1–7) in essential hypertension. J Pediatr 145:93–98
Mizuiri S, Hemmi H, Arita M, Aoki T, Ohashi Y, Miyagi M, Sakai K, Shibuya K, Hase H, Aikawa A (2011) Increased ACE and decreased ACE2 expression in kidneys from patients with IgA nephropathy. Nephron Clin Pract 117:c57–c66
Simões e Silva AC, Diniz JS, Pereira RM, Pinheiro SV, Santos RAS (2006) Circulating renin angiotensin system in childhood chronic renal failure: marked increase of angiotensin-(1–7) in end-stage renal disease. Pediatr Res 60:734–739
Luque M, Martin P, Martell N, Fernandez C, Brosnihan KB, Ferrario CM (1996) Effects of captopril related to increased levels of prostacyclin and angiotensin-(1–7) in essential hypertension. J Hypertens 14:799–805
Azizi M, Ménard J (2004) Combined blockade of the renin angiotensin system with angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Circulation 109:2492–2499
Kocks MJ, Lely AT, Boomsma F, de Jong PE, Navis G (2005) Sodium status and angiotensin-converting enzyme inhibition: effects on plasma angiotensin-(1–7) in healthy man. J Hypertens 23:597–602
Fernandes L, Fortes ZB, Casarini DE, Nigro D, Tostes RC, Santos RA, de Carvalho MH (2005) Role of PGI2 and effects of ACE inhibition on the bradykinin potentiation by angiotensin-(1–7) in resistance vessels of SHR. Regul Pept 127:183–189
Maia LG, Ramos MC, Fernandes L, de Carvalho MH, Campagnole-Santos MJ, Santos RAS (2004) Angiotensin-(1–7) antagonist A-779 attenuates the potentiation of bradykinin by captopril in rats. J Cardiovasc Pharmacol 43:685–691
Taal MW, Brenner BM (2000) Renoprotective benefits of RAS inhibition: from ACEI to angiotensin II antagonists. Kidney Int 57:1803–1817
Codreanu I, Perico N, Remuzzi G (2005) Dual blockade of the renin-angiotensin system: the ultimate treatment for renal protection? J Am Soc Nephrol 16 [Suppl 1]:S34–S38
Tallant EA, Ferrario CM, Gallagher PE (2005) Angiotensin-(1–7) inhibits growth of cardiac myocytes through activation of the Mas receptor. Am J Physiol 289:1560–1566
Tallant EA, Clark MA (2003) Molecular mechanisms of inhibition of vascular growth by angiotensin-(1–7). Hypertension 42:574–579
Gallagher PE, Tallant EA (2004) Inhibition of human lung cancer cell growth by angiotensin-(1–7). Carcinogenesis 25:2045–2052
Pereira RM, Santos RAS, Teixeira MM, Leite VHR, Costa LP, Barcelos L, Collares GB, Simões e Silva AC (2007) Renin Angiotensin System in a rat model of hepatic fibrosis: evidence for a protective role of Angiotensin-(1–7). J Hepatol 46:674–681
Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX, Greenberg BH (2005) Angiotensin-(1–7) binds to specific receptors on cardiac fibroblasts to initiate anti-fibrotic and anti-trophic effects. Am J Physiol 289:H2356–H2363
Santos RAS, Castro CH, Gava E, Pinheiro SV, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT, Ferreira AJ (2006) Impairment of in vitro and in vivo heart function in angiotensin-(1–7) receptor Mas knockout mice. Hypertension 47:996–1002
Kostenis E, Milligan G, Christopoulos A, Sanchez-Ferrer CF, Heringer-Walther S, Sexton PM, Gembardt F, Kellett E, Martini L, Vanderheyden P, Schultheiss HP, Walther T (2005) G-protein-coupled receptor Mas is a physiologic antagonist of the angiotensin II type 1 receptor. Circulation 111:1806–1813
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Simões e Silva, A.C., Flynn, J.T. The renin–angiotensin–aldosterone system in 2011: role in hypertension and chronic kidney disease. Pediatr Nephrol 27, 1835–1845 (2012). https://doi.org/10.1007/s00467-011-2002-y
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-011-2002-y